Literature DB >> 15286052

Light chains are a ligand for megalin.

R Bryan S Klassen1, Patricia L Allen, Vecihi Batuman, Kimberly Crenshaw, Timothy G Hammond.   

Abstract

Cubilin and megalin are giant glycoprotein receptors abundant on the luminal surface of proximal tubular cells of the kidney. We showed previously that light chains are a ligand for cubilin. As cubilin and megalin share a number of common ligands, we further investigated the ligand specificity of these receptors. Three lines of evidence suggest that light chains can also bind megalin: 1) anti-megalin antiserum largely displaces brush-border light chain binding and megalin-expressing BN-16 cell uptake more than anti-cubilin antiserum, 2) direct binding studies on isolated proteins using surface plasmon resonance techniques confirm that megalin binds light chains, and 3) light chains compete with known megalin ligands for brush-border membrane binding and BN-16 cell uptake. The megalin-light chain interaction is divalent ion dependent and similar for both kappa- and lambda-light chains. A fit of the data on light chain binding to megalin over a concentration range 0.078-2.5 mg/ml leads to an estimated dissociation constant of 6 x 10(-5) M, corresponding approximately to one light chain-binding site per megalin and in the same range for dissociation constants for cubilin binding. These data suggest that light chains bind the tandem megalin-cubilin complex. Megalin is the major mediator of light chain entry into megalin-expressing membrane such as the apical surface of proximal tubular epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15286052     DOI: 10.1152/japplphysiol.01090.2003

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  26 in total

1.  Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Paul W Sanders
Journal:  Am J Pathol       Date:  2011-11-10       Impact factor: 4.307

Review 2.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

Review 3.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

4.  Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Kristal J Aaron; Kolitha Basnayake; Paul W Sanders
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

Review 5.  Serum free light chain assessment in monoclonal gammopathy and kidney disease.

Authors:  Colin A Hutchison; Kolitha Basnayake; Paul Cockwell
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

6.  Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

Review 7.  Endocytic receptor LRP2/megalin-of holoprosencephaly and renal Fanconi syndrome.

Authors:  Thomas E Willnow; Annabel Christ
Journal:  Pflugers Arch       Date:  2017-05-11       Impact factor: 3.657

Review 8.  Dysproteinemias and Glomerular Disease.

Authors:  Nelson Leung; Maria E Drosou; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

9.  Presence of five conditioning film proteins are highly associated with early stent encrustation.

Authors:  Benjamin K Canales; LeeAnn Higgins; Todd Markowski; Lorraine Anderson; Qin A Li; Manoj Monga
Journal:  J Endourol       Date:  2009-09       Impact factor: 2.942

10.  Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.

Authors:  Colin A Hutchison; Stephen Harding; Pete Hewins; Graham P Mead; John Townsend; Arthur R Bradwell; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.